Cargando…

Tumor hypoxia drives immune suppression and immunotherapy resistance

Detalles Bibliográficos
Autores principales:	Ai, Midan, Budhani, Pratha, Sheng, Jie, Balasubramanyam, Sadhana, Bartkowiak, Todd, Jaiswal, Ashvin R, Ager, Casey R, Haria, Dhwani D, Curran, Michael A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652503/ http://dx.doi.org/10.1186/2051-1426-3-S2-P392

Ejemplares similares

The homeoprotein DLX4 controls inducible nitric oxide synthase-mediated angiogenesis in ovarian cancer
por: Trinh, Bon, et al.
Publicado: (2015)

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
por: Bartkowiak, Todd, et al.
Publicado: (2015)

HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer
por: Lifang, Yang, et al.
Publicado: (2008)

Longevity or hypoxia: who’s driving?
por: Pamenter, Matthew E., et al.
Publicado: (2019)

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
por: Reilley, Matthew J., et al.
Publicado: (2019)

Tumor hypoxia as a driving force in genetic instability
por: Luoto, Kaisa R, et al.
Publicado: (2013)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

Tumor Hypoxia Drives Genomic Instability
por: Tang, Ming, et al.
Publicado: (2021)

SHP-1: the next checkpoint target for cancer immunotherapy?
por: Watson, H. Angharad, et al.
Publicado: (2016)

MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma
por: de Azevedo, Ricardo A., et al.
Publicado: (2020)

Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
por: Daniel, S. K., et al.
Publicado: (2019)

Identification of gene signatures related to hypoxia and angiogenesis in pancreatic cancer to aid immunotherapy and prognosis
por: Li, Xiushen, et al.
Publicado: (2023)

Hypoxia drives the assembly of the multienzyme purinosome complex
por: Doigneaux, Cyrielle, et al.
Publicado: (2020)

Pericyte, but not astrocyte, hypoxia inducible factor-1 (HIF-1) drives hypoxia-induced vascular permeability in vivo
por: Baumann, Julia, et al.
Publicado: (2022)

Cancer cachexia impairs neural respiratory drive in hypoxia but not hypercapnia
por: Fields, Daryl P., et al.
Publicado: (2018)

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy
por: Lei, Josh Haipeng, et al.
Publicado: (2021)

Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin
por: Wakhloo, Debia, et al.
Publicado: (2020)

A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models
por: Ling, Binbing, et al.
Publicado: (2017)

Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment
por: Wei, Jinfen, et al.
Publicado: (2022)

Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
por: Park, Jang Hyun, et al.
Publicado: (2022)

The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
por: Janji, Bassam, et al.
Publicado: (2022)

Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

In Vitro/In Vivo Toxicity Evaluation and Quantification of Iron Oxide Nanoparticles
por: Patil, Ujwal S., et al.
Publicado: (2015)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

Schizophrenia Detection Using Machine Learning Approach from Social Media Content
por: Bae, Yi Ji, et al.
Publicado: (2021)

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
por: Ager, Casey R, et al.
Publicado: (2023)

MK2 drives progression of pancreas and colon cancers by suppressing CD8(+) T cell cytotoxic function and is a potential immunotherapy target
por: Jacenik, Damian, et al.
Publicado: (2023)

Iron‐Phosphorus Feedbacks Drive Multidecadal Oscillations in Baltic Sea Hypoxia
por: Jilbert, Tom, et al.
Publicado: (2021)

Carbon dioxide protects simulated driving performance during severe hypoxia
por: Bloomfield, Peter Michael, et al.
Publicado: (2023)

Hypoxia and IL-24 drive a sterile wound healing pathway
por: Bordon, Yvonne
Publicado: (2023)

Tongxinluo Reverses the Hypoxia-suppressed Claudin-9 in Cardiac Microvascular Endothelial Cells
por: Liu, Kun, et al.
Publicado: (2016)

Radix Scrophulariae extracts (harpagoside) suppresses hypoxia-induced microglial activation and neurotoxicity
por: Sheu, Shiow-Yunn, et al.
Publicado: (2015)

Immune response drives outcomes in prostate cancer: implications for immunotherapy
por: Meng, Jialin, et al.
Publicado: (2020)

Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy
por: Dai, Zhujiang, et al.
Publicado: (2022)

Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha
por: Zhang, Chao, et al.
Publicado: (2017)

Editorial: Advances in Combination Tumor Immunotherapy
por: Curran, Michael A., et al.
Publicado: (2015)

Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)–mediated induction of the long noncoding RNA NICI
por: Lauer, Victoria, et al.
Publicado: (2020)

Hypoxia drives transient site-specific copy gain and drug-resistant gene expression
por: Black, Joshua C., et al.
Publicado: (2015)

Incomplete proline catabolism drives premature sperm aging
por: Yen, Chia‐An, et al.
Publicado: (2021)

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy
por: Li, Yiliang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ag9vaek0e6fe1ocab0kv82piqs